EXCLUSIVE-Prenatal 実験（する） developed with Chinese 軍の 蓄える／店s 遺伝子 data
By Kirsty Needham and Clare Baldwin
July 7 (Reuters) - A prenatal 実験（する） taken by millions of 妊娠している women globally was developed by Chinese 遺伝子 company BGI Group in 共同 with the Chinese 軍の and is 存在 used by the 会社／堅い to collect genetic data, a Reuters review of 公然と 利用できる 文書s 設立する.
The 報告（する）／憶測 is the first to 明らかにする／漏らす that the company 共同製作するd with the People's 解放 Army (PLA) to develop and 改善する the 実験（する）, taken in 早期に pregnancy, 同様に as the 範囲 of BGI's 貯蔵 and 分析 of the data. The 部隊d 明言する／公表するs sees BGI's 成果／努力s to collect and analyse human 遺伝子 data as a 国家の 安全 脅し (see the story in-depth here https://www.reuters.com/調査／捜査するs/special-報告（する）／憶測/health-磁器-bgi-dna).
中国's biggest genomics 会社／堅い, BGI began marketing the 実験（する） abroad in 2013. Branded NIFTY, it is の中で the world's 最高の，を越す selling 非，不，無-invasive prenatal 実験（する）s (NIPT). These 審査する a 見本 of 血 from a 妊娠している woman to （悪事，秘密などを）発見する abnormalities such as 負かす／撃墜する's syndrome in a developing foetus.
So far more than 8 million women globally have taken BGI's prenatal 実験（する）s, BGI has said. NIFTY is sold in at least 52 countries, 含むing Britain, Europe, Canada, Australia, Thailand and India, but not the 部隊d 明言する／公表するs.
BGI uses leftover 血 見本s sent to its 研究室／実験室 in Hong Kong and genetic data from the 実験（する）s for 全住民 研究, the company 確認するd to Reuters. Reuters 設立する the genetic data of over 500 women who took the 実験（する）, 含むing women in Europe and Asia, is also 蓄える／店d in the 政府-基金d 中国 国家の GeneBank in Shenzhen, which BGI runs.
Reuters 設立する no 証拠 BGI 侵害する／違反するd privacy 協定s or 規則s; the company said it 得るs 調印するd 同意 and destroys overseas 見本s and data after five years. "At no 行う／開催する／段階 throughout the 実験（する）ing or 研究 過程 does BGI have 接近 to any identifiable personal data," the company said.
However, the 実験（する）' s privacy 政策 says data collected can be 株d when it is "直接／まっすぐに 関連した to 国家の 安全 or 国家の defence 安全" in 中国. BGI said it "has never been asked to 供給する - nor 供給するd - data from its NIFTY 実験（する）s to Chinese 当局 for 国家の 安全 or 国家の defence 目的s."
The U.S. 国家の Counterintelligence and 安全 中心, which has 以前 警告するd about Chinese 会社／堅いs collecting health data, said in 返答 to Reuters' findings that women taking the NIFTY 実験（する） abroad should be 関心d by a privacy 政策 that 許すs data to be 株d with Chinese 安全 機関s.
"非，不，無-invasive prenatal 実験（する）ing 道具s marketed by Chinese biotech 会社／堅いs serve an important 医療の 機能（する）／行事, but they can also 供給する another 機械装置 for the People's 共和国 of 中国 and Chinese biotech companies to collect genetic and genomic data from around the globe," the 中心 said.
中国's foreign 省 said Reuters' findings 反映するd "groundless 告訴，告発s and smears" of U.S. 機関s.
Other companies selling such prenatal 実験（する）s also re-use data for 研究. But 非，不，無 operate on the 規模 of BGI, scientists and ethicists say, or have BGI's links to a 政府 or its 跡をつける 記録，記録的な／記録する with a 国家の 軍の.
BGI began working with Chinese 軍の hospitals to 熟考する／考慮する the genomes of foetuses in 2010 and has published over a dozen 共同の 熟考する／考慮するs with PLA 研究員s to 裁判，公判 and 改善する its prenatal 実験（する）s, the Reuters review of more than 100 public 文書s showed.
The PLA General Hospital in Beijing and Third 軍の 医療の University in Chongqing ran 臨床の 裁判，公判s on the NIFTY 実験（する） in 2011. They worked with BGI 研究員s to 拡大する the genetic abnormalities the 実験（する） 審査するs for, papers published in 2019 and 2020 show.
In one example, the PLA General Hospital worked with BGI on the first Chinese prenatal 裁判，公判 to 審査する for dwarfism, which BGI later brought to market.
Also, a BGI 熟考する／考慮する published in 2018 used a 軍の スーパーコンピューター to re-analyse NIFTY data and 地図／計画する the prevalence of ウイルスs in Chinese women, look for 指示する人（物）s of mental illness in them, and えり抜く Tibetan and Uyghur 少数，小数派s to find links between their 遺伝子s and their 特徴.
同様に as genetic （警察などへの）密告，告訴（状） about the foetus and mother, the 実験（する）ing 過程 逮捕（する）s personal （警察などへの）密告，告訴（状）, such as the 顧客's country, 負わせる, 高さ, and 医療の history, によれば BGI computer code reviewed by Reuters. The 顧客's 指名する is not collected.
Reuters spoke to a woman who took the 実験（する） in 2020, a 32-year-old office 行政官／管理者 in Poland. She said that if she had known her data could be 株d with the Chinese 政府, or understood the extent of BGI's 第２位 研究, she would have chosen a different 実験（する）.
"I want to know what is happening with such 極度の慎重さを要する data about me, such as my genome and that of my child," said the woman, Emilia, who asked to be identified only by her first 指名する.
(報告（する）／憶測ing by Kirsty Needham in Sydney and Clare Baldwin in Hong Kong; 付加 報告（する）／憶測ing by Joanna Plucinska in Warsaw; Edited by Kevin Krolicki and Sara Ledwith)
